Venetoclax Plus Obinutuzumab Superior to FCR-BR for Patients With CLL | Blood Cancers Today
Venetoclax plus obinutuzumab demonstrates superior safety and efficacy compared with fludarabine-cyclophosphamide-rituximab and bendamustine-rituximab in patients with CLL.